Form 4: Incyte EVP & CMO Exercises Options, Sells Shares

Incyte's EVP & Chief Medical Officer, Steven H. Stein, exercised stock options and subsequently sold 5,233 shares of common stock for liquidity and diversification.

Summary

• Steven H. Stein, EVP & Chief Medical Officer of Incyte Corp (INCY), engaged in transactions on November 5, 2025.
• Stein exercised non-qualified stock options to acquire 1,194 shares of common stock at an exercise price of $83.83 per share.
• He also exercised non-qualified stock options to acquire 2,995 shares of common stock at an exercise price of $95.76 per share.
• Additionally, Stein exercised incentive stock options to acquire 1,044 shares of common stock at an exercise price of $95.76 per share.
• Following these exercises, Stein sold 5,233 shares of Incyte common stock at a price of $102.20 per share.
• The transactions were made pursuant to a Rule 10b5-1 plan, indicating they were pre-scheduled.
• After these transactions, Stein beneficially owns 102,886 shares of common stock, which includes 100,327 shares issuable from previously reported restricted stock units and earned performance shares that have not yet vested.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While an insider sale can sometimes be viewed negatively, this transaction involves the exercise of options and a subsequent sale, likely for liquidity or diversification, especially given it was pre-planned under a Rule 10b5-1 plan. The executive still retains substantial beneficial ownership, including a significant number of unvested shares.

Positives

• The executive realized a profit by exercising options at lower prices ($83.83 and $95.76) and selling shares at a higher market price ($102.20).
• The transaction was conducted under a Rule 10b5-1 plan, suggesting a pre-planned sale for personal financial management rather than a reaction to new, non-public information.

Negatives

• The executive reduced direct ownership of Incyte common stock by selling 5,233 shares.

Future Outlook

NA

Industry Context

This Form 4 filing details a routine insider transaction involving the exercise of stock options and subsequent sale of shares, which is a common occurrence in executive compensation within the biotechnology and pharmaceutical industry. Such transactions are typically for personal financial planning, diversification, or to cover tax obligations related to option exercises.

Stakeholder Impact

• Shareholders: Minor impact. The sale is a routine executive compensation event and was pre-planned, suggesting no new material information. The executive retains significant beneficial ownership, aligning interests with shareholders.
• Employees: No direct impact mentioned.

Key Dates

Keywords

Incyte Corp, INCY, Steven H. Stein, Insider Trading, Form 4, Stock Options, Executive Compensation, Rule 10b5-1